Long-Term Follow-Up from the Phase 1/2 MajesTEC-1 trial of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma

Amrita Y. Krishnan, MD, and Binod Dhakal, MD, provide an overview of the current treatment landscape in relapsed/refractory multiple myeloma.

Experts on multiple myeloma review the study design and results from MajesTEC-1, focusing on the efficacy and safety findings, and provide insights on adverse event management practices.

Following a review of recent data from MajesTEC-1 investigating teclistamab, the panel provides clinical insights on dosing and adverse event prophylaxis practices.

Amrita Y. Krishnan, MD, and Binod Dhakal, MD, discuss the clinical implications of data from MajesTEC-1 and provide key takeaways on the evolving relapsed/refractory multiple myeloma treatment landscape.

Amrita Y. Krishnan, MD, and Binod Dhakal, MD, gave a high-level overview of teclistamab use in the MajesTEC-1 trial.